Efficacy and Safety of Dapagliflozin in Treatment Naive or Treatment
Experienced Type 2 Diabetes Mellitus Patients from South Punjab,


  • Author- Qazi Masroor Ali, Ali Imran, Raheel Khan, Maria Masroor, Sohail Tariq, Ghulam Mohy U Din Chaudhary


To gather clinical data regarding weight reduction, glycemic control and safety of dapagliflozin oral tablets in Type 2 Diabetes Mellitus patients from South Punjab, Pakistan.


This prospective clinical trial was conducted at Department of Medicine, Bahawal Victoria Hospital, Bahawalpur from July 2019 to June 2020. A total of 400 patients of genders aged above 18 years, BMI > 25 and having type-2 diabetes mellitus were enrolled. Patients losing planned follow ups were excluded from the final analysis. Dapagliflozin as 5mg or 10mg was prescribed. Patients were asked to follow up after every 2 weeks up till 24 weeks. Change in weight, HbA1c, FBS, RBS and blood pressure was recorded during the follow ups.


  Out of a total of 400 patients enrolled, 238 (59.5%) were female. Overall, mean age was 48.06+10.38 years. Mean baseline body weight was noted to 78.81±15.67 kg. Mean HbA1c (%) was recorded to be 9.14+2.12. Statistically significantly reduction in body weight was noted at 4 weeks, 12 weeks and 24 weeks when compared to baseline values (p


  Dapagliflozin was found to have good efficacy in terms of body weight reduction and improvement in glycemic control among patients with T2DM. Overall, safety profile of dapagliflozin was good.


Efficacy, safety, dapagliflozin, HbA1c, body weight.